Dalhousie University's Faculty of Medicine has made headlines with a pioneering advancement in treating Fabry disease, a rare genetic disorder that has long challenged medical researchers. In a world-first clinical trial known as the FACTs study, Dalhousie Medicine researchers achieved rapid enzyme circulation in the first patient treated, marking a potential shift from lifelong biweekly infusions to a one-time gene therapy solution. This breakthrough not only stabilizes disease progression but also slashes treatment costs, offering hope to the roughly 300 Canadians living with Fabry disease.

The development underscores Dalhousie University's role as a leader in rare disease research within Canadian higher education. Located in Halifax, Nova Scotia, the university's collaborative efforts with sites in Toronto and Calgary have produced results that could redefine enzyme replacement therapy (ERT) for lysosomal storage disorders. As higher education institutions increasingly drive medical innovation, this trial highlights how university-led initiatives can deliver tangible patient benefits while advancing scientific knowledge.

What is Fabry Disease?

Fabry disease, or Anderson-Fabry disease (full name: α-galactosidase A deficiency), is an X-linked lysosomal storage disorder caused by mutations in the GLA gene on the X chromosome. This leads to deficient or absent activity of the enzyme α-galactosidase A (α-Gal A), resulting in the accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids in cells, particularly lysosomes of endothelial cells, vascular smooth muscle cells, and podocytes.

Symptoms typically emerge in childhood or adolescence for males, who are more severely affected due to hemizygosity. Early signs include acroparesthesias (burning pain in extremities), angiokeratomas (skin lesions), hypohidrosis (reduced sweating), and gastrointestinal issues. Over time, multi-organ involvement leads to progressive kidney failure, hypertrophic cardiomyopathy, cerebrovascular events like strokes, and reduced life expectancy—often to 50-60 years without treatment. Females, as heterozygous carriers, exhibit variable expressivity due to X-inactivation, with symptoms ranging from mild to severe.

In Canada, prevalence is estimated at 1 in 40,000 males and up to twice that in females, though newborn screening and registries like the Canadian Fabry Disease Initiative (CFDI) suggest underdiagnosis. Dalhousie researchers note higher incidence in Nova Scotia's South Shore, around 1 in 8,000, linked to founder effects.

Dalhousie University's Longstanding Commitment to Rare Disease Research

Dalhousie Medicine has a storied history in lysosomal storage disorders. Dr. Michael West, a nephrologist at the QEII Health Sciences Centre and professor at Dalhousie, has been pivotal. Partnering with Dr. Jeffrey Medin—whose work at University Health Network (UHN) in Toronto pioneered the gene therapy approach since the 1990s—the team secured Canadian Institutes of Health Research (CIHR) funding for the FACTs trial.

This builds on Dalhousie's broader strengths in genetics and hematology. The university hosts advanced facilities like the Centre for Precision Health and the IWK Health Centre for pediatric research, fostering interdisciplinary teams. In Canadian higher education, Dalhousie exemplifies how regional universities can lead national trials, collaborating with UHN and Foothills Medical Centre in Calgary. Such partnerships amplify impact, training the next generation of clinician-scientists while addressing Canada's rare disease challenges.

The FACTs Trial: A Step-by-Step Breakdown

The Fabry Disease Clinical Research and Therapeutics (FACTs) trial, launched in 2016, was the first global test of lentiviral (LV)-mediated gene therapy for classical Fabry disease. Here's how it works:

• Patient Selection: Five adult males with confirmed GLA mutations and on ERT were enrolled across Halifax, Toronto, and Calgary.
• Stem Cell Mobilization: Hematopoietic stem cells (HSCs) harvested from bone marrow via G-CSF mobilization and apheresis.
• Ex Vivo Transduction: HSCs transduced with a lentiviral vector carrying the functional GLA gene under a strong promoter, ensuring high α-Gal A expression.
• Myeloablation and Infusion: Mild conditioning chemotherapy clears niche for transduced HSCs, followed by autologous reinfusion.
• Engraftment and Production: Modified HSCs engraft in bone marrow, differentiate into macrophages/monocytes that secrete α-Gal A into circulation, crossing the blood-brain barrier unlike standard ERT.

This autologous approach minimizes immunogenicity. In the first patient, α-Gal A appeared in plasma within 12 hours post-infusion, reaching near-normal levels (~50% of healthy) by day 7—far faster than predicted.

Groundbreaking Clinical Results from Five-Year Follow-Up

Published in Clinical and Translational Medicine (DOI: 10.1002/ctm2.70073), the 5-year end-of-study data are transformative. All patients achieved sustained α-Gal A production, with vector-marked cells persisting. Four showed major biomarker reductions (e.g., plasma Gb3, lyso-Gb3). Three discontinued ERT permanently—one for over 6 years.

Kidney function stabilized in advanced cases; no Fabry-related clinical events occurred, unlike CFDI registry controls on ERT. Safety: Two grade 3 infusion reactions (resolved), no vector-related adverse events. Full trial results confirm durable efficacy.

Patient Perspectives: Life Beyond Infusions

Ryan Deveau, treated early in Halifax, exemplifies impact. Pre-trial, biweekly ERT dominated life; post-infusion, he went 3.5+ years infusion-free. "I would basically forget that I had Fabry disease," Deveau shared. Family time reclaimed, energy restored—he pursued activities impossible before.

Other patients report pain relief, fatigue reduction. Quality-of-life scores improved 3.7-5.3 points in subsets. Compared to CFDI controls, FACTs participants fared better, highlighting therapy's edge over ERT.

Healthcare Economics: Millions Saved for Canadian Systems

ERT costs ~$300,000 CAD annually per patient. FACTs trial saved $300,000/year across five patients, totaling $3.7 million over time—exceeding CIHR investment. Provinces like Nova Scotia, Ontario, Alberta benefit directly. Scaling could transform rare disease funding, freeing resources for other needs.

Dalhousie economist analyses project broader savings: fewer transplants, strokes. In higher ed context, university research ROI shines, justifying public investment in institutions like Dalhousie.

For details on Canadian rare disease economics, see Fabry stats overview.

Safety Profile and Ongoing Challenges

LV vectors proved safe: no insertional mutagenesis, replication-competent lentivirus, or malignancy. Transient cytopenias resolved. Long-term monitoring continues via CFDI.

Challenges: Access for females (X-inactivation variability), pediatrics, advanced disease. Vector dose optimization needed. Dalhousie plans Phase II (25-30 patients, including women).

Future Directions: Scaling Gene Therapy at Dalhousie

Team partners with biotech for GMP manufacturing, larger trials. Potential FDA/Health Canada approval positions Canada as gene therapy leader. Dalhousie eyes expanded applications to other LSDs (e.g., MPS I).

In Canadian higher ed, this bolsters Dalhousie's NIRF-like rankings, attracts talent. Links to FACTs trial registry.

Implications for Canadian Higher Education and Research

Dalhousie's success exemplifies university-driven innovation. Amid funding pressures, CIHR model proves value. Trains postdocs, MD-PhDs; boosts enrollment in genomics programs. Peers like UBC, McMaster eye similar trials.

Policy-wise, advocates risk-sharing agreements for rare diseases, per recent analyses.

Photo by Sangharsh Lohakare on Unsplash

Dalhousie's Broader Impact in Medical Research

Beyond Fabry, Dalhousie excels in cardiology, neurology—aligning with Fabry's comorbidities. Faculty like West mentor next-gen researchers, fostering Canada's biotech ecosystem. This positions Halifax as rare disease hub.